Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes

被引：0
|
作者：
Wei, Andrew H. [1 ,2 ,3 ]
Seymour, John F. [1 ,2 ]
机构：
[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
基金：
英国医学研究理事会;
关键词：
myelodysplastic syndromes; Hypomethylating agents; lenalidomide; CONVENTIONAL CARE REGIMENS; AZACITIDINE; LENALIDOMIDE; CLASSIFICATION; COMBINATION;
D O I：
10.1111/bjh.18240
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hypomethylating agents remain the current standard of care for patients with higher-risk myelodysplastic syndromes. Ades et al. report outcomes from a randomised 'pick-a-winner' study design that examined the addition of either lenalidomide, valproic acid or idarubicin in combination with azacitidine, compared to azacitidine alone. Commentary on: Ades et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: GFM's 'pick a winner' trial, with the impact of somatic mutations. Br J Haematol 2022 (Online ahead of print). doi: 10.1111/bjh.18193.
引用
下载
收藏
页码：415 / 418
页数：4
相关论文
共 50 条
  • [1] Enhancing Survival Outcomes in the Management of Patients With Higher-Risk Myelodysplastic Syndromes
    Gore, Steven D.
    Hermes-DeSantis, Evelyn R.
    CANCER CONTROL, 2009, 16 (04) : 2 - 10
  • [2] Overview of the Management of Higher-Risk Myelodysplastic Syndromes
    Singh, Abhay
    Carraway, Hetty E.
    CANCER JOURNAL, 2023, 29 (03): : 160 - 167
  • [3] Drug development in higher-risk myelodysplastic syndromes
    Sangeetha Venugopal
    Mikkael A. Sekeres
    Blood Cancer Journal, 14 (1)
  • [4] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    Dinmohamed, A. G.
    van Norden, Y.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    LEUKEMIA, 2016, 30 (08) : 1795 - +
  • [5] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    A G Dinmohamed
    Y van Norden
    A A van de Loosdrecht
    M Jongen-Lavrencic
    Leukemia, 2016, 30 : 1795 - 1796
  • [6] Decitabine treatment of patients with higher-risk myelodysplastic syndromes
    Steensma, David P.
    LEUKEMIA RESEARCH, 2009, 33 : S12 - S17
  • [7] How we treat higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Cutler, Corey
    BLOOD, 2014, 123 (06) : 829 - 836
  • [8] Improving clinical trials in higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2022, 35 (04)
  • [9] Advances in the management of higher-risk myelodysplastic syndromes: future prospects
    Gener-Ricos, Georgina
    Rodriguez-Sevilla, Juan Jose
    Urrutia, Samuel
    Bataller, Alex
    Bazinet, Alexandre
    Garcia-Manero, Guillermo
    LEUKEMIA & LYMPHOMA, 2024, 65 (09) : 1233 - 1244
  • [10] Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S56 - S59
12345